Jorge B Cannata-andía
Cannata-Andía, Jorge B.
VIAF ID: 7081483 (Personal)
Permalink: http://viaf.org/viaf/7081483
Preferred Forms
-
-
- 100 0 _ ‡a Jorge B Cannata-andía
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Dual-specificity phosphatases are implicated in severe hyperplasia and lack of response to FGF23 of uremic parathyroid glands from rats. | |
Effect of aluminium on calcium-sensing receptor expression, proliferation, and apoptosis of parathyroid glands from rats with chronic renal failure | |
The effect of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population | |
Effects of estradiol, calcitriol and both treatments combined on bone histomorphometry in rats with chronic kidney disease and ovariectomy | |
The effects of lifestyle, dietary dairy intake and diabetes on bone density and vertebral deformity prevalence: the EVOS study | |
ERA-EDTA--a dynamic association moving forward. | |
European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP) | |
Falls explain between-center differences in the incidence of limb fracture across Europe. | |
H2O2 regulation of vascular function through sGC mRNA stabilization by HuR | |
Health-related quality of life and radiographic vertebral fracture. | |
High performance liquid chromatography methods for studying protein binding of aluminium in human serum in the absence and in the presence of desferrioxamine. | |
High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression | |
The hypercalcaemia of CYP24A1 inactivation: new ways to improve diagnosis and treatment | |
Hypokinetic azotemic osteodystrophy | |
Identification, cloning and characterization of an aldo-keto reductase from Trypanosoma cruzi with quinone oxido-reductase activity. | |
Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells | |
An improved wave-vector frequency-domain method for nonlinear wave modeling. | |
Indirect regulation of PTH by estrogens may require FGF23. | |
Influence of body mass index on the association of weight changes with mortality in hemodialysis patients | |
Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. | |
Low calcidiol levels and risk of progression of aortic calcification | |
Low transcriptional activity haplotype of matrix metalloproteinase 1 is less frequent in bicuspid aortic valve patients. | |
Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. | |
Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a Spanish population | |
Mechanisms of aluminum-induced microcytosis: lessons from accidental aluminum intoxication | |
Micellar versus reversed phase liquid chromatography for the determination of desferrioxamine and its chelates with aluminium and iron in uremic serum | |
Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis? | |
Mitochondrial DNA and TFAM gene variation in early-onset myocardial infarction: evidence for an association to haplogroup H | |
Natural antioxidants and vascular calcification: a possible benefit | |
Necrotic concentrations of cisplatin activate the apoptotic machinery but inhibit effector caspases and interfere with the execution of apoptosis | |
New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy | |
New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. | |
A novel mutation in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia in a family with two uncommon parathyroid hormone polymorphisms | |
Nutritional status in dialysis patients: a European consensus | |
Observational studies: the hazard and other gods | |
Oral active vitamin D is associated with improved survival in hemodialysis patients | |
Parathyroid gland regulation: contribution of the in vivo and in vitro models. | |
Pathogenesis, prevention and management of low-bone turnover. | |
The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS. | |
Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease. | |
Phosphorus and survival: key questions that need answers | |
Plasma Cardiotrophin-1 as a Marker of Hypertension and Diabetes-Induced Target Organ Damage and Cardiovascular Risk. | |
The position of strontium ranelate in today's management of osteoporosis. | |
Preliminary results from a multicentre enquiry. | |
Prevalence of osteoporosis in men and determinants of changes in bone mass in a non-selected Spanish population | |
Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study | |
Prevention of aluminium exposure through dialysis fluids. Analysis of changes in the last 8 years | |
Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability. | |
Progression of vascular calcifications is associated with greater bone loss and increased bone fractures | |
Reconsidering the importance of long-term low-level aluminum exposure in renal failure patients | |
Reference values for trace and ultratrace elements in human serum determined by double-focusing ICP-MS. | |
REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain. | |
Renal osteodystrophy in Iberoamerica. | |
Reproducibility of a Questionnaire on Risk Factors for Osteoporosis in a Multicentre Prevalence Survey: The European Vertebral Osteoporosis Study | |
Role of iron metabolism in absorption and cellular uptake of aluminum. | |
Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol | |
Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Introduction | |
Supplementation of vitamin D and calcium: advantages and risks | |
Targeted genomic disruption of H-ras and N-ras has no effect on early renal changes after unilateral ureteral ligation | |
Time course and functional correlates of post-transplant aluminium elimination | |
Ultrafiltrable aluminium after very low doses of desferrioxamine | |
The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease. | |
Use of phosphate-binding agents is associated with a lower risk of mortality | |
Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration | |
Validity of Self-Report of Fractures: Results from a Prospective Study in Men and Women Across Europe | |
Variants in cardiac GATA genes associated with bicuspid aortic valve | |
Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. | |
Vascular calcifications, vertebral fractures and mortality in haemodialysis patients | |
Viability and functionality of fresh and cryopreserved human hyperplastic parathyroid tissue tested in vitro | |
Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure | |
Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. | |
Vitamin D receptor gene polymorphisms, bone mass, bone loss and prevalence of vertebral fracture: differences in postmenopausal women and men | |
Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels | |
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. | |
What should the characteristics and attributes of an accredited nephrology training programme be? Looking for high standards |